StreetInsider.com News Articles

Form EFFECT CNS Pharmaceuticals,

Wed, 27 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260527/26552922.html

Form EFFECT CNS Pharmaceuticals,

Wed, 27 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260527/26552922.html

Form 424B3 CNS Pharmaceuticals,

Tue, 26 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260526/26551110.html

Form 424B3 CNS Pharmaceuticals,

Tue, 26 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260526/26551110.html

Form 4 CNS Pharmaceuticals, For: May 18 Filed by: Charles Faith L.

Wed, 20 May 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260520/26525831.html

Form 4 CNS Pharmaceuticals, For: May 18 Filed by: Charles Faith L.

Wed, 20 May 2026 09:03:00 -0400

si-local-file:///var/storage/secattach/20260520/26525831.html

Form D CNS Pharmaceuticals,

Tue, 19 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260519/26522383.html

Form D CNS Pharmaceuticals,

Tue, 19 May 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260519/26522383.html

CNS Pharmaceuticals (CNSP) files for 9.79M share offering by selling stockholders

Tue, 19 May 2026 17:00:08 -0400

CNS Pharmaceuticals (NASDAQ: CNSP) has filed for up to 9,793,479 share offering by selling stockholders.

CNS Pharmaceuticals (CNSP) files for 9.79M share offering by selling stockholders

Tue, 19 May 2026 17:00:08 -0400

CNS Pharmaceuticals (NASDAQ: CNSP) has filed for up to 9,793,479 share offering by selling stockholders.

Form S-3 CNS Pharmaceuticals,

Tue, 19 May 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260519/26522255.html

Form S-3 CNS Pharmaceuticals,

Tue, 19 May 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260519/26522255.html

Form SCHEDULE 13G/A CNS Pharmaceuticals, Filed by: Stonepine Capital Management, LLC

Fri, 15 May 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260515/26507822.html

Form SCHEDULE 13G/A CNS Pharmaceuticals, Filed by: Stonepine Capital Management, LLC

Fri, 15 May 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260515/26507822.html

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

Thu, 14 May 2026 08:00:00 -0400

Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy

Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287

New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy

HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

Thu, 14 May 2026 08:00:00 -0400

Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287

New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy

Form 10-Q CNS Pharmaceuticals, For: Mar 31

Thu, 14 May 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260514/26490114.html

Form 10-Q CNS Pharmaceuticals, For: Mar 31

Thu, 14 May 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260514/26490114.html

CNS Pharmaceuticals raises $22.5 million in private placement

Mon, 04 May 2026 07:09:32 -0400

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced it has entered into securities purchase agreements for a private placement financing expected to generate gross proceeds of approximately $22.5 million before fees and expenses.

The Houston-based biotechnology company said the private placement includes participation from institutional healthcare investors ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners.

Under the terms of the agreements, CNS is selling 650,000 shares of common stock at $2.30 per share and pre-funded warrants to purchase 9,143,479 shares at $2.299 per warrant. The pre-funded warrants carry an exercise price of $0.001 per share. The transaction is expected to close on

Form 8-K CNS Pharmaceuticals, For: May 04

Mon, 04 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260504/26420838.html

Form 8-K CNS Pharmaceuticals, For: May 04

Mon, 04 May 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260504/26420838.html

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

Mon, 04 May 2026 07:00:00 -0400

The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners

Proceeds expected to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy

HOUSTON, TX / ACCESS Newswire / May 4, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, announced today that it has entered into securities purchase agreements for a private placement financing

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

Mon, 04 May 2026 07:00:00 -0400

The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners

Form 10-K/A CNS Pharmaceuticals, For: Dec 31

Thu, 30 Apr 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260430/26408986.html

Form 10-K/A CNS Pharmaceuticals, For: Dec 31

Thu, 30 Apr 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260430/26408986.html